A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) – SELECT – PsA 1 Randomizovaná, dvojitě zaslepená studie fáze 3 srovnávající upadacitinib s placebem a adalimumabem u pacientů s aktivní psoriatickou artritidou s anamnézou nedostatečné odpovědi na nejméně jeden nebiologickÝ antirevmatickÝ přípravek modifikující průběh onemocnění (DMARD) - SELECT - PsA 1

Trial Profile

A Phase 3, Randomized, Double-Blind, Study Comparing Upadacitinib (ABT-494) to Placebo and to Adalimumab in Subjects with Active Psoriatic Arthritis Who Have a History of Inadequate Response to at Least One Non-Biologic Disease Modifying Anti-Rheumatic Drug (DMARD) – SELECT – PsA 1 Randomizovaná, dvojitě zaslepená studie fáze 3 srovnávající upadacitinib s placebem a adalimumabem u pacientů s aktivní psoriatickou artritidou s anamnézou nedostatečné odpovědi na nejméně jeden nebiologickÝ antirevmatickÝ přípravek modifikující průběh onemocnění (DMARD) - SELECT - PsA 1

Recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Aug 2018

At a glance

  • Drugs Upadacitinib (Primary) ; Adalimumab
  • Indications Psoriatic arthritis
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT - PsA 1
  • Sponsors AbbVie
  • Most Recent Events

    • 11 Apr 2018 Planned End Date changed from 17 Feb 2023 to 30 Jan 2023.
    • 29 Mar 2018 Planned End Date changed from 18 Jan 2023 to 17 Feb 2023.
    • 28 Feb 2018 Planned End Date changed from 21 Sep 2022 to 18 Jan 2023.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top